[go: up one dir, main page]

MX2016000219A - Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos. - Google Patents

Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos.

Info

Publication number
MX2016000219A
MX2016000219A MX2016000219A MX2016000219A MX2016000219A MX 2016000219 A MX2016000219 A MX 2016000219A MX 2016000219 A MX2016000219 A MX 2016000219A MX 2016000219 A MX2016000219 A MX 2016000219A MX 2016000219 A MX2016000219 A MX 2016000219A
Authority
MX
Mexico
Prior art keywords
dihydroxyphenyl
methods
compositions
neurotransmitter
compounds
Prior art date
Application number
MX2016000219A
Other languages
English (en)
Other versions
MX384131B (es
Inventor
Frank Schneider
Chengzhi Zhang
David S Goldstein
Courtney Holmes
Rudolf-Giesbert Alken
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of MX2016000219A publication Critical patent/MX2016000219A/es
Publication of MX384131B publication Critical patent/MX384131B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con nuevos moduladores dihidroxifenilo de niveles de neurotransmisores, composiciones farmacéuticas de los mismos y métodos de uso de los mismos. (ver Fórmula).
MX2016000219A 2013-07-08 2014-07-08 Compuestos neurotransmisores de dihidroxifenilo, composiciones y métodos. MX384131B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361843549P 2013-07-08 2013-07-08
US201462010098P 2014-06-10 2014-06-10
PCT/US2014/045731 WO2015006315A1 (en) 2013-07-08 2014-07-08 Dihydroxyphenyl neurotransmitter compounds, compositions and methods

Publications (2)

Publication Number Publication Date
MX2016000219A true MX2016000219A (es) 2016-05-31
MX384131B MX384131B (es) 2025-03-14

Family

ID=52133230

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000219A MX384131B (es) 2013-07-08 2014-07-08 Compuestos neurotransmisores de dihidroxifenilo, composiciones y métodos.

Country Status (16)

Country Link
US (5) US20150011630A1 (es)
EP (2) EP3611159B1 (es)
JP (1) JP6567515B2 (es)
KR (1) KR20160041912A (es)
CN (1) CN105473545B (es)
AU (2) AU2014287418A1 (es)
BR (1) BR112016000338A8 (es)
CA (1) CA2917159C (es)
CL (1) CL2016000019A1 (es)
EA (1) EA201600093A1 (es)
HK (1) HK1221713A1 (es)
IL (2) IL243488A0 (es)
MX (1) MX384131B (es)
PE (1) PE20160556A1 (es)
SG (2) SG11201510764QA (es)
WO (1) WO2015006315A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109640989A (zh) * 2016-08-30 2019-04-16 施万生物制药研发Ip有限责任公司 用于治疗神经性起立性低血压的化合物
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN113993523A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗抑郁症和其他各种病症
JP2022553371A (ja) * 2019-10-25 2022-12-22 キュラセン セラピューティクス インコーポレイテッド α１Ａ－ＡＲ部分アゴニストを用いて神経障害を治療するための方法
WO2021247963A1 (en) * 2020-06-05 2021-12-09 Senda Biosciences, Inc. (s)-alpha-fluoromethyltyrosine as decarboxylase inhibitors for use in the treatment of hypotension

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3360726D1 (en) * 1982-01-14 1985-10-17 Sumitomo Chemical Co Process for producing threo-3-(3,4-dihydroxyphenyl)serine
CA1223602A (en) 1983-05-25 1987-06-30 Naohito Ohashi Process for producing 3-(3,4-dihydroxyphenyl) serine
JP3764179B2 (ja) 1994-07-05 2006-04-05 克寛 西野 運動・意識または言語障害の機能改善剤
DE19619510A1 (de) 1995-05-18 1996-11-21 Sumitomo Chemical Co Verfahren zur Herstellung von Threo-3-(3,4-dihydroxyphenyl)serin
JP3489319B2 (ja) 1996-03-12 2004-01-19 住友化学工業株式会社 カルボン酸誘導体、その製造法および用途
JPH115738A (ja) 1997-06-15 1999-01-12 Katsuhiro Nishino 脳虚血に伴う神経脱落症状の予防剤および超急性期治療剤
US6376531B1 (en) * 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
WO2005084330A2 (en) 2004-03-02 2005-09-15 Synergia Pharma, Inc. Compositions and methods for treating nasal congestion
PT1991522T (pt) * 2006-02-17 2016-08-23 Imphar Ag Derivados de catecolamina deuterada e medicamentos compreendendo os referidos compostos
BRPI0808647A2 (pt) 2007-03-09 2014-08-12 Chelsea Therapeutics Inc Método para tratar a síndrome de sensibilidade central, método para reduzir, eliminar ou prevenir a dor associada à fibromialgia, kit útil para o tratamento de uma síndrome de sensibilidade central.
US20080227830A1 (en) * 2007-03-12 2008-09-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
NZ581707A (en) 2007-05-07 2011-05-27 Chelsea Therapeutics Inc Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US7745665B2 (en) 2007-06-04 2010-06-29 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
US20100172916A1 (en) * 2008-11-10 2010-07-08 Auspex Pharmaceuticals, Inc. Substituted hydroxyphenylamine compounds
WO2010132128A1 (en) 2009-05-14 2010-11-18 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognitve functions in individuals with down syndrome and/or alzheimer's disease
KR20120101323A (ko) 2009-07-01 2012-09-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 트레오-3-(3,4-디히드록시페닐)-ｌ-세린의 제조방법
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
US20130253061A1 (en) 2012-03-20 2013-09-26 Chelsea Therapeutics, Inc. Method of droxidopa synthesis

Also Published As

Publication number Publication date
US20180280511A1 (en) 2018-10-04
JP2016529228A (ja) 2016-09-23
CA2917159C (en) 2022-08-23
HK1216747A1 (zh) 2016-12-02
US20220072131A1 (en) 2022-03-10
EP3611159A1 (en) 2020-02-19
KR20160041912A (ko) 2016-04-18
IL243488A0 (en) 2016-02-29
IL266767A (en) 2019-07-31
CN105473545B (zh) 2017-08-04
EP3019467A4 (en) 2017-03-15
EP3019467A1 (en) 2016-05-18
PE20160556A1 (es) 2016-06-11
SG11201510764QA (en) 2016-01-28
SG10201800166UA (en) 2018-02-27
MX384131B (es) 2025-03-14
CA2917159A1 (en) 2015-01-15
US20170319694A1 (en) 2017-11-09
EA201600093A1 (ru) 2016-08-31
HK1221713A1 (zh) 2017-06-09
BR112016000338A8 (pt) 2020-01-07
CL2016000019A1 (es) 2016-11-04
AU2014287418A1 (en) 2016-01-28
CN105473545A (zh) 2016-04-06
EP3611159B1 (en) 2023-01-25
WO2015006315A1 (en) 2015-01-15
JP6567515B2 (ja) 2019-08-28
US20190374642A1 (en) 2019-12-12
US20150011630A1 (en) 2015-01-08
BR112016000338A2 (pt) 2017-08-22
AU2018253594A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
MX2015009719A (es) Inhibidores benzoquinolona de vmat2.
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
EA201591748A1 (ru) Модуляторы p2x7
MX2018001430A (es) Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
SV2014004770A (es) Nuevos derivados de pirrol, su procedimiento de preparación y los composiciones farmacéuticas que los contienen
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CR20150524A (es) Compuestos de heteroarilo y sus usos
CR20150462A (es) Inhibidores de erk y sus usos
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
GT201400297A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
MX381719B (es) Compuestos cbd fluorados, composiciones y usos de los mismos.
EA201591959A1 (ru) Ингибиторы акк и их применение
EA201591960A1 (ru) Ингибиторы акк и их применение
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
EA201590887A1 (ru) Композиция
EA201591451A1 (ru) Модуляторы flap
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
UY35653A (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MX2017007377A (es) Compuestos organicos.
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio